论文部分内容阅读
目的:评价新辅助化疗中Ki-67的表达情况对三阴性乳腺癌(TNBC)获得病理完全缓解(pCR)的预测作用。方法:通过互联网检索相关文献,应用Review Manager软件对数据进行处理,系统评价Ki-67表达情况与TNBC在新辅助化疗中获得pCR的关系。结果:Ki-67基因高表达的TNBC患者pCR率明显高于Ki-67基因低表达的TNBC患者,总体合并优势比(OR)为7.35,95%CI:2.39～22.60,文献之间无明显异质性,无明显发表偏倚。结论:Ki-67可作为新辅助化疗中预测TNBC化疗敏感性的标志。
Objective: To evaluate the predictive value of Ki-67 expression in neoadjuvant chemotherapy for pathologic complete remission (pCR) in triple negative breast cancer (TNBC). METHODS: The relevant literature was retrieved through the Internet. The data were processed with Review Manager software to systematically evaluate the relationship between Ki-67 expression and TNBC pCR in neoadjuvant chemotherapy. Results: The pCR rate of TNBC patients with high expression of Ki-67 gene was significantly higher than that of TNBC patients with low expression of Ki-67 gene. The overall combined odds ratio (OR) was 7.35 and 95% CI: 2.39 ~ 22.60, no significant difference Qualitative, no obvious publication bias. Conclusions: Ki-67 can be used as a marker for predicting TNBC chemosensitivity in neoadjuvant chemotherapy.